Lofgren's Syndrome Human Leukocyte Antigen Strongly Influences the Disease Course

被引:158
作者
Grunewald, Johan [1 ]
Eklund, Anders [1 ]
机构
[1] Karolinska Univ Hosp Solna, Div Resp Med, Dept Med, Stockholm, Sweden
基金
英国医学研究理事会;
关键词
Lofgren's syndrome; sarcoidosis; HLA; SARCOIDOSIS PATIENTS; RISK-FACTORS; PULMONARY SARCOIDOSIS; ARTHRITIS; PROGRESSION; PARAMETERS; PROGNOSIS; HAPLOTYPE; FLUID; ONSET;
D O I
10.1164/rccm.200807-1082OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale Sarcoidosis may consist of a number of distinct disease entities, one of which could be Lofgren's syndrome. Patients with Lofgren's syndrome have an acute onset of erythema nodosum (EN) and/or perarticular inflammation or arthritis of the ankles, with bilateral hilar lymphadenopathy (and in some cases parenchymal Infiltrates) and usually fever. There is a known association between HLA-DRB1*03 and Lofgren's syndrome. Objectives: To Investigate whether human leukocyte antigen type Influences clinical manifestations, Including the disease course In Lofgren's syndrome. Methods: We clinically characterized and HLA-DRB1 typed 301 patients with Lofgren's syndrome. A total of 275 of the patients were followed for more than 2 years and classified as having a non-resolving or a resolving disease. Measurements and Main Results: Almost every DRB1*03-positive patient had a resolving disease within 2 years, and 49% of the DRB1*03-negative patients developed a nonresolving disease. Mucosal granulomas were identified significantly more often in DRB1*03-negative patients. Among DRB1*03-negative patients who were treated with oral steroids at disease onset, 80% developed a nonresolving disease. Conclusions: Patients with Lofgren's syndrome have a different disease course depending on whether they are DRB1*03 positive or not. This observation has clinical implications, and by comparing DRB1*03-positive and DRB1*03-negative patients with Lofgren's syndrome, we can search for additional markers of importance for developing a resolving or a nonresolving disease, respectively.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 32 条
[11]  
HEDFORS E, 1983, TISSUE ANTIGENS, V22, P200
[12]  
HILLERDAL G, 1984, AM REV RESPIR DIS, V130, P29
[13]   Medical progress: Sarcoidosis [J].
Iannuzzi, Michael C. ;
Rybicki, Benjamin A. ;
Teirstein, Alvin S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2153-2165
[14]  
JAMES DG, 1961, BRIT MED J, V5229, P853
[15]  
LOFGREN S, 1952, ACTA MED SCAND, V142, P259
[16]  
LOFGREN S, 1952, ACTA MED SCAND, V142, P265
[17]  
LOFGREN S, 1953, ACTA MED SCAND, V145, P425
[18]   Genetic aspects in sarcoidosis [J].
Luisetti, M ;
Beretta, A ;
Casali, L .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) :768-780
[19]   Lofgren's syndrome revisited:: A study of 186 patients [J].
Mañá, J ;
Gómez-Vaquero, C ;
Montero, A ;
Salazar, A ;
Marcoval, J ;
Valverde, J ;
Manresa, F ;
Pujol, R .
AMERICAN JOURNAL OF MEDICINE, 1999, 107 (03) :240-245
[20]  
MARTINETTI M, 1995, AM J RESP CRIT CARE, V152, P557, DOI 10.1164/ajrccm.152.2.7633707